Silexion Therapeutics (SLXN) Change in Receivables (2023 - 2025)
Silexion Therapeutics (SLXN) posted quarterly Change in Receivables of -$4000.0 for Q1 2025, down 109.09% year-over-year from $44000.0 in Q1 2024, and down 123.53% quarter-over-quarter from $17000.0 in Q3 2024.
Silexion Therapeutics (SLXN) Change in Receivables (2023 - 2025) Analysis & Trends
Silexion Therapeutics' Change in Receivables history runs 3 years deep, the most recent figure standing at -$4000.0 for Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Silexion Therapeutics | 266,692.97 | -1.96 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -4,000.00 |
| Mar 31, 2025 | -4,000.00 |
| Sep 30, 2024 | 17,000.00 |
| Sep 30, 2024 | 17,000.00 |
| Jun 30, 2024 | -2,000.00 |
| Jun 30, 2024 | -2,000.00 |
| Mar 31, 2024 | 44,000.00 |
| Mar 31, 2024 | 44,000.00 |
| Sep 30, 2023 | -24,000.00 |
| Sep 30, 2023 | -24,000.00 |
| Jun 30, 2023 | 20,000.00 |
| Jun 30, 2023 | 20,000.00 |